Onvuzosiran Provides Deep and Sustained Reduction of Plasma Kallikrein Levels for the Treatment of HAE
June, 2026
European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting, June 2026
ADX-324 is novel siRNA drug that provides deep and long-lasting suppression of prekallikrein levels for HAE
February, 2026
The American Academy of Allergy, Asthma & Immunology Annual Meeting 2026
Interim Phase 1 Study Results of ADX-038: A Novel siRNA Against Complement Factor B, and Next Steps in IgAN and C3 Glomerulopathy (C3G)
November, 2025
The American Society of Nephrology (ASN) Kidney Week 2025
